Conferences

ESMO Asia 2019

Panelists urge better designs, more global focus for phase I trials

November 26, 2019

SINGAPORE – While a lot of focus is placed on phase III trials and the subsequent approvals, panelists during the ESMO Asia Congress pointed to the importance of designing the right kind of phase I trials, from reaching global populations to using appropriate endpoints.

ESMO Asia 2019

Population-based cancer registries needed for treatment, prevention efforts

November 26, 2019

By David Ho

No Comments

SINGAPORE – Population-based cancer registries were a frequent focus of discussion at the ESMO Asia Congress.

ESMO Asia 2019

Quality of life and quality of studies take stage as Takeda reports solid NSCLC findings

November 26, 2019

By David Ho

No Comments

SINGAPORE – Takeda Pharmaceutical Co. Ltd. presented new findings from its phase III ALTA-1L trial evaluating its Alunbrig (brigatinib) vs. crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) who had not received a prior ALK inhibitor, showing Alunbrig reduced the risk of disease progression or death by 76% after more than two years of follow-up.

ESMO Asia Congress 2019

Moving West to East: Panelists focus on Asia-prevalent cancers, NGS tests and precision oncology

November 26, 2019

By David Ho

No Comments

SINGAPORE – As the ESMO Asia Congress 2019 brought 3,679 participants from all over the Asia-Pacific region and beyond to Singapore’s Suntec Convention & Exhibition Centre, the focus, unsurprisingly, was on developments and challenges relevant to the oncology community.

Chinatrials 12 Summit

China looking to close gap in cell therapy market; CAR T development advancing fast

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – Although China still has a way to go to approve any CAR T therapy, clinical development is robust with various targets being studied, and the regulatory environment is improving, cell therapy experts said at the Chinatrials 12 Summit.

Chinatrials 12 Summit

Is China ready for first-in-class? Not quite, but we must go ahead with innovation, experts say

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – As Chinese biotech companies talk more about innovation, one question is whether they are ready to move into first-in-class drugs from me-too and fast follow-up drugs. To biotech executives, the China first approval for Fibrogen Inc.'s roxadustat, a first-in-class small molecule for amenorrhea, is a wake-up call.

Chinatrials 12 Summit

Too many PD-1s? Facing a competitive landscape, Chinese firms seek ways to stand out

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – With abundant venture capital and favorable policies, Chinese biotech companies are actively turning themselves from generic makers into innovation-driven players, but the market is getting crowded by too many companies focusing on the same area and even the same targets, a reality that is leading to a lack of differentiation in biotech innovation.

Chinatrials 12 Summit

Foreign pharma can leverage China’s regulatory pragmatism, patients and lower trial costs

November 19, 2019

By Elise Mak

No Comments

SHANGHAI – Now is the time for foreign pharmaceutical companies to include China in their strategies, as the country's recent regulatory reform, vast patient pool and lower costs represent opportunities to score approvals faster, said experts at the Chinatrials12 Summit.

AusBiotech 201

National stem cell roadmap provides cohesive vision, funding for Australia's regenerative medicine sector

November 12, 2019

By Tamra Sami

No Comments

MELBOURNE, Australia – Although Australia was one of the first movers in the regenerative medicine space, until now a cohesive plan for investing in regenerative medicine was holding the sector back.

AusBiotech 2019

Australia's biotechs grapple with reimbursement system for cell therapies

November 6, 2019

By Tamra Sami

No Comments

Although Australia's Therapeutic Goods Administration (TGA) approved its first CAR T therapy in 2018, the country is lacking a system to reimburse those advanced therapies, and industry is calling on government to revalue gene therapies.

Conferences, BioWorld Asia
RSS

Panelists urge better designs, more global focus for phase I trials

Population-based cancer registries needed for treatment, prevention efforts

Quality of life and quality of studies take stage as Takeda reports solid NSCLC findings

Moving West to East: Panelists focus on Asia-prevalent cancers, NGS tests and precision oncology

China looking to close gap in cell therapy market; CAR T development advancing fast

Is China ready for first-in-class? Not quite, but we must go ahead with innovation, experts say

Too many PD-1s? Facing a competitive landscape, Chinese firms seek ways to stand out

Foreign pharma can leverage China’s regulatory pragmatism, patients and lower trial costs

National stem cell roadmap provides cohesive vision, funding for Australia's regenerative medicine sector

Australia's biotechs grapple with reimbursement system for cell therapies

Popular Stories

Bioworld MedTech’s Oncology Extra

Analysis by U.K. startup Medbelle highlights extent of drug pricing disparity

FDA gives thumbs up to Cochlear’s implantable bone conduction hearing system

Buoyed by optimism and love of family, former FDA chief Frank Young leaned into storms

Biopharma companies continue their strong momentum in November

BioWorld Premium

Conferences, BioWorld Asia RSS

Popular Stories

BioWorld Premium

Conferences, BioWorld Asia
RSS